Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes
摘要:
Several pyrazolo-, triazolo-, and imidazolopyrimidines were synthesized and evaluated as inhibitors of DPP4. Of these three classes of compounds, the imidazolopyrimidines displayed the greatest potency and demonstrated excellent selectivity over the other dipeptidyl peptidases. SAR evaluation for these scaffolds was described as they may represent potential treatments for type 2 diabetes. (C) 2010 Elsevier Ltd. All rights reserved.
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
申请人:Meng Wei
公开号:US20060178377A1
公开(公告)日:2006-08-10
Compounds are provided having the formula (I)
wherein R, X, Y, A and n are as defined herein.
提供化合物的公式(I),其中R、X、Y、A和n的定义如下。
WO2006/71752
申请人:——
公开号:——
公开(公告)日:——
AZOLOPYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS
申请人:Bristol-Myers Squibb Company
公开号:EP1836206B1
公开(公告)日:2011-03-09
US7635699B2
申请人:——
公开号:US7635699B2
公开(公告)日:2009-12-22
Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes
作者:Robert P. Brigance、Wei Meng、Aberra Fura、Thomas Harrity、Aiying Wang、Robert Zahler、Mark S. Kirby、Lawrence G. Hamann
DOI:10.1016/j.bmcl.2010.06.063
日期:2010.8
Several pyrazolo-, triazolo-, and imidazolopyrimidines were synthesized and evaluated as inhibitors of DPP4. Of these three classes of compounds, the imidazolopyrimidines displayed the greatest potency and demonstrated excellent selectivity over the other dipeptidyl peptidases. SAR evaluation for these scaffolds was described as they may represent potential treatments for type 2 diabetes. (C) 2010 Elsevier Ltd. All rights reserved.